159 related articles for article (PubMed ID: 25990328)
1. [Fatal tuberculosis during treatment with ruxolitinib].
Keizer S; Gerritsen R; Jauw Y; Janssen J; Koopman B; Bresser P
Ned Tijdschr Geneeskd; 2015; 159():A8650. PubMed ID: 25990328
[TBL] [Abstract][Full Text] [Related]
2. Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Tsukamoto Y; Kiyasu J; Tsuda M; Ikeda M; Shiratsuchi M; Ogawa Y; Yufu Y
Intern Med; 2018 May; 57(9):1297-1300. PubMed ID: 29279479
[TBL] [Abstract][Full Text] [Related]
3. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.
Colomba C; Rubino R; Siracusa L; Lalicata F; Trizzino M; Titone L; Tolomeo M
BMC Res Notes; 2012 Oct; 5():552. PubMed ID: 23039051
[TBL] [Abstract][Full Text] [Related]
4. Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.
Ogai A; Yagi K; Ito F; Domoto H; Shiomi T; Chin K
Intern Med; 2022 Apr; 61(8):1271-1278. PubMed ID: 34565769
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge.
Palandri F; Polverelli N; Catani L; Vianelli N
Ann Hematol; 2015 Mar; 94(3):519-20. PubMed ID: 25172457
[No Abstract] [Full Text] [Related]
6. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
[TBL] [Abstract][Full Text] [Related]
7. Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis.
Pepeler MS; Özkurt ZN; Güzel ÖT; Akyürek N
J Infect Dev Ctries; 2018 Oct; 12(10):926-928. PubMed ID: 32004164
[TBL] [Abstract][Full Text] [Related]
8. Fatal ruxolitinib-related JC virus meningitis.
Ballesta B; González H; Martín V; Ballesta JJ
J Neurovirol; 2017 Oct; 23(5):783-785. PubMed ID: 28791626
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib and tuberculosis: A case report with brief review.
Tiwari N; Singh A; Singh B; Verma SP; Tripathi AK
Indian J Tuberc; 2022 Jul; 69(3):354-358. PubMed ID: 35760486
[TBL] [Abstract][Full Text] [Related]
10. Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.
Dioverti MV; Abu Saleh OM; Tande AJ
Infect Dis (Lond); 2018 May; 50(5):381-387. PubMed ID: 29251529
[TBL] [Abstract][Full Text] [Related]
11. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
12. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Mead AJ; Milojkovic D; Knapper S; Garg M; Chacko J; Farquharson M; Yin J; Ali S; Clark RE; Andrews C; Dawson MK; Harrison C
Br J Haematol; 2015 Jul; 170(1):29-39. PubMed ID: 25824940
[TBL] [Abstract][Full Text] [Related]
13. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.
Lescuyer S; Ledoux MP; Gravier S; Natarajan-Amé S; Duval C; Maloisel F; Mauvieux L; Toussaint E; Fornecker LM; Herbrecht R
Int J Infect Dis; 2019 Mar; 80():134-136. PubMed ID: 30639623
[TBL] [Abstract][Full Text] [Related]
14. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.
Aylı M; Özcan M; Cengiz Seval G
Turk J Haematol; 2015 Jun; 32(2):180-3. PubMed ID: 26316489
[TBL] [Abstract][Full Text] [Related]
16. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib for the treatment of primary myelofibrosis.
Swaim SJ
Am J Health Syst Pharm; 2014 Mar; 71(6):453-62. PubMed ID: 24589536
[TBL] [Abstract][Full Text] [Related]
18. Disseminated tuberculosis associated with ruxolitinib.
Hopman RK; Lawrence SJ; Oh ST
Leukemia; 2014 Aug; 28(8):1750-1. PubMed ID: 24625550
[No Abstract] [Full Text] [Related]
19. [Ruxolitinib prescription in myelofibrosis].
Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]